Heligenics, Jackson Lab Partner to Study Breast Cancer Gene Variants

Under the terms of the deal, Heligenics will apply its GigaAssay, a massively parallelized platform for assaying molecular functions of single cells in culture, to ERBB2 variants. The resulting data will be included in the Jackson Laboratory’s JAX Clinical Knowledgebase, a web-based resource for interpreting cancer genomic profiles.

The Las Vegas-based company said that the partnership aims to identify the impact of thousands of poorly understood ERBB2 mutations and how they cause breast and other cancers, as well as retrospectively analyze how gene mutation/functional library data can improve patient outcomes.

Source: https://www.genomeweb.com/cancer/heligenics-jackson-lab-partner-study-breast-cancer-gene-variants